Kura Oncology (KURA) Amortization of Deferred Charges (2023 - 2026)

Kura Oncology has reported Amortization of Deferred Charges over the past 4 years, most recently at $106000.0 for Q1 2026.

  • Quarterly Amortization of Deferred Charges fell 20.3% to $106000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $488000.0 through Mar 2026, down 8.61% year-over-year, with the annual reading at $515000.0 for FY2025, 1.53% down from the prior year.
  • Amortization of Deferred Charges was $106000.0 for Q1 2026 at Kura Oncology, up from $103000.0 in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $141000.0 in Q3 2025 and troughed at $103000.0 in Q4 2025.
  • The 4-year median for Amortization of Deferred Charges is $122000.0 (2023), against an average of $124692.3.
  • Year-over-year, Amortization of Deferred Charges rose 17.65% in 2024 and then fell 26.43% in 2025.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $119000.0 in 2023, then grew by 17.65% to $140000.0 in 2024, then dropped by 26.43% to $103000.0 in 2025, then rose by 2.91% to $106000.0 in 2026.
  • Per Business Quant, the three most recent readings for KURA's Amortization of Deferred Charges are $106000.0 (Q1 2026), $103000.0 (Q4 2025), and $141000.0 (Q3 2025).